Iqbal Hussain Sells 6,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) General Counsel Iqbal Hussain sold 6,000 shares of the stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total value of $134,460.00. Following the completion of the sale, the general counsel directly owned 105,386 shares of the company’s stock, valued at $2,361,700.26. The trade was a 5.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $23.02 on Friday. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The business has a 50 day simple moving average of $20.34 and a 200-day simple moving average of $15.84. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $24.57. The company has a market capitalization of $3.08 billion, a P/E ratio of -12.86 and a beta of 1.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in Centessa Pharmaceuticals by 4.8% in the second quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock worth $252,000 after acquiring an additional 870 shares in the last quarter. HighMark Wealth Management LLC increased its position in shares of Centessa Pharmaceuticals by 0.6% in the second quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company’s stock valued at $3,118,000 after buying an additional 1,500 shares in the last quarter. HighVista Strategies LLC increased its position in shares of Centessa Pharmaceuticals by 4.3% in the second quarter. HighVista Strategies LLC now owns 40,684 shares of the company’s stock valued at $535,000 after buying an additional 1,664 shares in the last quarter. Trexquant Investment LP increased its position in shares of Centessa Pharmaceuticals by 1.1% in the first quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock valued at $3,796,000 after buying an additional 2,810 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after buying an additional 3,194 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analyst Upgrades and Downgrades

CNTA has been the subject of several recent research reports. Wall Street Zen raised Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, October 11th. Guggenheim reaffirmed a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a report on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. Truist Financial began coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 price target for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.38.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.